Earnings Summary

Dyne Therapeutics, Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2024. On a quarterly growth basis, Dyne Therapeutics, Inc has generated -100% fall in its revenue since last 3-months.

Dyne Therapeutics, Inc’s net profit fell -54.48% since last year same period to $-65.65Mn in the Q1 2024. On a quarterly growth basis, Dyne Therapeutics, Inc has generated 1.48% jump in its net profits since last 3-months.

Dyne Therapeutics, Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2024. On a quarterly growth basis, Dyne Therapeutics, Inc has generated -Inf% fall in its net profit margins since last 3-months.

Dyne Therapeutics, Inc’s earning per share (EPS) estimates for the current quarter stand at -0.72 - a 10% jump from last quarter’s estimates.

Dyne Therapeutics, Inc’s earning per share (EPS) estimates for the current year stand at -0.72.

Dyne Therapeutics, Inc’s earning per share (EPS) fell -3.85% since last year same period to -0.81 in the Q1 2024. This indicates that the Dyne Therapeutics, Inc has generated -3.85% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Dyne Therapeutics, Inc’s return on assets (ROA) stands at -0.41.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Dyne Therapeutics, Inc’s return on equity (ROE) stands at -0.72.